Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Transcriptomic profile reveals gender-specific molecular mechanisms driving multiple sclerosis progression.
CNS diseases and uveitis.
Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosis.
Substance Name: ONO 4641
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
Optical coherence tomography and its use in optical neuritis and multiple sclerosis.
Interventions to evaluate fitness to drive among people with chronic conditions: Systematic review of literature.
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Epstein-Barr virus cause of multiple sclerosis.
[2011: What's new in dysimmune neuropathies.]
Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis.
Personality characteristics in MS patients: The role of avoidant personality.
Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer¿s disease and multiple sclerosis.
The Opioid System and Brain Development: Effects of Methadone on the Oligodendrocyte Lineage and the Early Stages of Myelination.
Crossfit training changes brain-derived neurotrophic factor and irisin levels at rest, after wingate and progressive tests, and improves aerobic capacity and body composition of young physically active men and women.
Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.
Origin and evolution of deep brain stimulation.
Network meta-analysis models to account for variability in treatment definitions: application to dose effects.
A new computerised cognitive test for the detection of information processing speed impairment in multiple sclerosis.
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis.
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Gait variability and disability in multiple sclerosis.
Cerebrospinal fluid analysis.

Pages